Matches in SemOpenAlex for { <https://semopenalex.org/work/W2044999739> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W2044999739 endingPage "1" @default.
- W2044999739 startingPage "1" @default.
- W2044999739 abstract "The field of inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), has undergone many notable advances in recent years in terms of aetiological understanding, diagnostic techniques and management strategies. In this supplement, leading specialists in the field of gastroenterology contribute their expertise on these and other topics concerning IBD. The supplement begins with a focus on the application of genetic testing in the clinical management of IBD, followed by an examination of the role of bacteria in IBD onset and perpetuation. Novel techniques for diagnostic imaging and strategies for the prevention of post-surgical recurrence of IBD will also be discussed. Many individuals with IBD are prescribed 5-aminosalicylic acid (5-ASA; mesalazine), which is particularly useful for the treatment of mild attacks of UC or CD, and in reducing the chance of a flare-up in patients with inactive UC. For this reason, we have chosen to highlight key issues related to optimizing aminosalicylate treatment, including the important topic of how to control and improve adherence to therapy. Patients with long-standing and extensive UC and CD have an increased risk of colorectal cancer compared with the general population, and this issue is highlighted in terms of both detecting and reducing this risk. Finally, we will focus on the thought-provoking topic of new approaches to the treatment of IBD. This will encompass a debate on medical therapy versus colectomy for severe instances of UC, plus a discussion of biological therapies for the management of CD. We hope that the information contained in this supplement will prove useful for clinicians in their understanding of the causes of IBD and in providing practical solutions for the future management of their patients. The experts who have contributed to this supplement met to discuss these issues at a congress in Madrid, Spain, in November 2005. The meeting was sponsored by an unrestricted educational grant from Ferring Pharmaceuticals, manufacturer of Pentasa® (mesalazine) for the treatment of mild-to-moderate UC and CD and the maintenance of remission of UC and CD." @default.
- W2044999739 created "2016-06-24" @default.
- W2044999739 creator A5070475894 @default.
- W2044999739 creator A5086121907 @default.
- W2044999739 date "2006-10-01" @default.
- W2044999739 modified "2023-09-23" @default.
- W2044999739 title "Introduction: new approaches to the detection and management of inflammatory bowel disease: from genetic testing to treatment strategies" @default.
- W2044999739 doi "https://doi.org/10.1111/j.1365-2036.2006.03051.x" @default.
- W2044999739 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16961736" @default.
- W2044999739 hasPublicationYear "2006" @default.
- W2044999739 type Work @default.
- W2044999739 sameAs 2044999739 @default.
- W2044999739 citedByCount "0" @default.
- W2044999739 crossrefType "journal-article" @default.
- W2044999739 hasAuthorship W2044999739A5070475894 @default.
- W2044999739 hasAuthorship W2044999739A5086121907 @default.
- W2044999739 hasBestOaLocation W20449997391 @default.
- W2044999739 hasConcept C126322002 @default.
- W2044999739 hasConcept C137627325 @default.
- W2044999739 hasConcept C177713679 @default.
- W2044999739 hasConcept C2778260677 @default.
- W2044999739 hasConcept C2779134260 @default.
- W2044999739 hasConcept C2779174533 @default.
- W2044999739 hasConcept C2780479503 @default.
- W2044999739 hasConcept C2780673598 @default.
- W2044999739 hasConcept C2908647359 @default.
- W2044999739 hasConcept C71924100 @default.
- W2044999739 hasConcept C99454951 @default.
- W2044999739 hasConceptScore W2044999739C126322002 @default.
- W2044999739 hasConceptScore W2044999739C137627325 @default.
- W2044999739 hasConceptScore W2044999739C177713679 @default.
- W2044999739 hasConceptScore W2044999739C2778260677 @default.
- W2044999739 hasConceptScore W2044999739C2779134260 @default.
- W2044999739 hasConceptScore W2044999739C2779174533 @default.
- W2044999739 hasConceptScore W2044999739C2780479503 @default.
- W2044999739 hasConceptScore W2044999739C2780673598 @default.
- W2044999739 hasConceptScore W2044999739C2908647359 @default.
- W2044999739 hasConceptScore W2044999739C71924100 @default.
- W2044999739 hasConceptScore W2044999739C99454951 @default.
- W2044999739 hasIssue "s3" @default.
- W2044999739 hasLocation W20449997391 @default.
- W2044999739 hasLocation W20449997392 @default.
- W2044999739 hasOpenAccess W2044999739 @default.
- W2044999739 hasPrimaryLocation W20449997391 @default.
- W2044999739 hasRelatedWork W2024552926 @default.
- W2044999739 hasRelatedWork W2085189110 @default.
- W2044999739 hasRelatedWork W2105981361 @default.
- W2044999739 hasRelatedWork W2119817537 @default.
- W2044999739 hasRelatedWork W2321902261 @default.
- W2044999739 hasRelatedWork W2408939568 @default.
- W2044999739 hasRelatedWork W2418837291 @default.
- W2044999739 hasRelatedWork W2470266787 @default.
- W2044999739 hasRelatedWork W2984572983 @default.
- W2044999739 hasRelatedWork W3145059027 @default.
- W2044999739 hasVolume "24" @default.
- W2044999739 isParatext "false" @default.
- W2044999739 isRetracted "false" @default.
- W2044999739 magId "2044999739" @default.
- W2044999739 workType "article" @default.